Skip to content
OpenCapital
Get started

Rigel Pharmaceuticals RIGL Unrecognized Tax Benefits

Unrecognized Tax Benefits at other companies

Nuvation Bio logo
Nuvation BioNUVB
$10.13M+37.1%
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$53.96M+31.1%
Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND
$17.08M+20.4%

Other financials

Income statement

See full
Revenue$58.8M+10.3%
Gross profit$54.2M+10.8%
Operating income$11.9M-7.0%
Net income$8.7M-24.4%
EPS (diluted)$0.44-30.2%

Balance sheet

See full
Cash & equivalents$24.5M-46.6%
Total debt$68.4M+5,079%
Total equity$399.9M+2,054%
Total assets$504.6M+187%

Cash flow

See full
Operating cash flow$2.7M+405%
CapEx$73.0K—
Free cash flow-$22.0M—

Valuation

See full
Market cap$684.39M+102%
Enterprise value$728.29M+148%
P/E1.9×-7.2×
P/S2.3×+0.6×

Profitability

See full
Gross margin93.4%+3.7pp
Operating margin41.6%+19.9pp
Net margin121.5%+103pp
FCF margin-61.7%—

Returns & leverage

See full
Return on equity174.1%—
Debt / equity0.2×+0.1×
Current ratio2.6×+0.4×

Where this comes from

Reported directly by Rigel Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:UnrecognizedTaxBenefits.

The official record: Rigel Pharmaceuticals’s 10-K, filed March 3, 2026, on SEC EDGAR. View the filing →

Ask your AI about Rigel Pharmaceuticals's unrecognized tax benefits.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Rigel Pharmaceuticals's unrecognized tax benefits?
Rigel Pharmaceuticals (RIGL) reported unrecognized tax benefits of $9.05M in Q4 2025.
What is the long-term trend for Rigel Pharmaceuticals's unrecognized tax benefits?
Over 3 years (2022 to 2025), Rigel Pharmaceuticals's unrecognized tax benefits has grown at a -1.3% compound annual growth rate (CAGR), from $9.43M to $9.05M.
What does unrecognized tax benefits mean?
This represents the amount of tax benefits from uncertain tax positions that have not been recognized in the financial statements because they do not meet the 'more-likely-than-not' threshold. It reflects the company's exposure to potential tax audits and disputes with tax authorities. This is a key indicator of tax-related legal and financial risk.